The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...

Spending the day facing the challenges of kidney patients helps workers at a CT pharmaceutical company understand disease and ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

STORY German pharmaceutical company sees great benefits from CIIE spillover effectSHOOTING TIME Recent footageDATELINE Nov 10 2024LENGTH 00011 ...

Boehringer Ingelheim has halted development of an obesity drug from Gubra that it originally pledged to advance back in 2017, ...

Privately-held German drugmaker Boehringer Ingelheim and researchers from the Stanley Center for Psychiatric Research at the ...

The state-of-the-art research and development center in Georgia will help improve the health and wellbeing of animals ...

Ingelheim: Boehringer Ingelheim and researchers from the Stanley Center for Psychiatric Research at the Broad Institute of ...

Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity.

A while back, pharmaphorum web editor Nicole Raleigh spoke with Daniel Schwenk, senior principal clinical data manager at Boehringer Ingelheim, and Andrea Kloeble, Product Owner, Boehringer ...

Abdulla also aims to further strengthen relationships with regional governments and key healthcare stakeholders to ensure ...